Tag Archives: Psychiatric

A Clinical Drug Trial Gone Wrong and the Unfinished Business of the Somalia Affair

As public awareness has grown in relation to the adverse health effects of the anti-malarial drug mefloquine in military veterans, much of the media attention has focused on a series of drug trials conducted by the Australian Defence Force in … Continue reading

Posted in Advocacy, Clinical Drug Trials | Tagged , , , , , , , , , , , | 1 Comment

PTSD as a “Diagnosis of Convenience”: Mefloquine, Tafenoquine and the Prevalence of Neuropsychiatric Disorders in ADF Veterans of East Timor and Bougainville

One of the problems that has perplexed many Australian government officials and veterans advocates in recent years is the disproportionately high number of Australian Defence Force (ADF) East Timor veterans who have been diagnosed with post-traumatic stress disorder (PTSD). PTSD is … Continue reading

Posted in Advocacy, Clinical Drug Trials, Research | Tagged , , , , , , , , , , , , , | 3 Comments

Featured Research – J. Livezey et al, Prolonged Neuropsychiatric Symptoms in a Military Service Member Exposed to Mefloquine

“A 32-year-old male developed neuropsychiatric symptoms 2 weeks after starting mefloquine 250 mg/week for malaria prophylaxis. He continued to take the medication for the next 4 months. Initial symptoms included vivid dreams and anxiety, as well as balance problems. These symptoms persisted and … Continue reading

Posted in Research | Tagged , , , , , , , | Leave a comment

Seroxat Study 329 Opens The Pandora’s Box For All Bogus Anti-Depressant Studies…. — GSK : Licence To (K) ill (Documenting GSK And Seroxat)

http://www.madinamerica.com/2016/05/researchers-deconstruct-ghostwritten-industry-trial-for-antidepressant/ Interview: Researchers Deconstruct Ghostwritten Industry Trial for Antidepressant In The News May 14, 2016 Researchers, Jon Jureidini, Jay Amsterdam and Leemon McHenry, have taken a closer look at the data from a randomized control trial of citalopram (Celexa) that … Continue reading

Posted in Clinical Drug Trials | Tagged , , , | 1 Comment

CDC Staff Accused Injured U.S. Veteran of “Malingering” in Response to Official Drug Regulator Safety Warning on Mefloquine

FDA Black Box Warning In 2013 the U.S. Food and Drug Administration (FDA) issued a “black box” warning regarding the safety of the anti-malarial drug mefloquine. This is the most serious warning issued by the FDA, which in this case … Continue reading

Posted in Advocacy, Media, Research, Support | Tagged , , , , , , , , , , , , , | Leave a comment

British Parliamentary Inquiry Report on the Use of Lariam™ (Mefloquine) for Military Personnel to be Published on 24 May 2016

The British Parliament’s Defence Select Committee is publishing its report, “An acceptable risk? The use of Lariam for military personnel” on Tuesday 24 May 2016 at 00.01am. Report This is the Committee’s Fourth Report of Session 2015–16 (HC 567) and it can … Continue reading

Posted in Advocacy, Clinical Drug Trials, Media, Our Stories | Tagged , , , , , , , , , , , , | 1 Comment

Stuart McCarthy – Diagnosis and Management of Mefloquine Toxicosis in Military Veterans, Part 1

Mefloquine toxicosis, or “mef tox”, is a serious health problem that probably afflicts many tens of thousands of military veterans globally. The anti-malarial drug mefloquine (or Lariam™), like several other drugs from the same family of synthetic quinolines, is known … Continue reading

Posted in Advocacy, Research, Support | Tagged , , , , , , , | 6 Comments

Featured Research (2014) – Remington L. Nevin, Mefloquine and Post-traumatic Stress Disorder

Mefloquine (previously marketed in the United States as Lariam [F Hoffmann-LaRoche Ltd, Basel, Switzerland]) is a neurotoxic quinoline-derivative originally developed by the US military for treatment and prophylaxis of malaria. Originally the US military’s preferred antimalarial drug, mefloquine has been widely … Continue reading

Posted in Research | Tagged , , , , , , | 1 Comment